An Early Phase 1 interventional study of Vibrotactile stimulation in PARKINSON DISEASE (Disorder), sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by University of Colorado, Denver · Early Phase 1, Interventional, and Basic science
Investigation on whether and how vibrotactile stimulation applied on the fingertips affects beta power in the subthalamic nucleus.
With a randomized order, two stimulation patterns are applied for one hour each on the fingertips of Parkinson's patients with deep brain stimulation, while periodically recording from subthalamic nucleus (STN) local field potentials (LFPs). The randomized vibrotactile stimulation (RVS) power is expected to reduce neuronal synchronization and LFP beta power. The All-on stimulation pattern is not expected to reduce neuronal synchronization and LFP beta power.
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's enrollment of 12 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →University of Colorado, Denver is the lead sponsor of 1,499 studies on the registry; 315 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 89 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants receives the RVS stimulation pattern followed by the All-on pattern
Device: Vibrotactile stimulation
Participants receives the All-on stimulation pattern followed by the RVS pattern
Device: Vibrotactile stimulation
Vibration patterns applied on the fingertips.
Beta band power
13-30 Hz frequency band
Time frame: At baseline (pre-intervention) and after 30 min of intervention
MDS-UPDRS Part III
Movement disorder assessment for Parkinson's disease motor symptoms of the upper extremity. The scale is from 0 to 4 for the items in the MDS-UPDRS Part III, where 0 represents normal function (and 4 is worse).
Time frame: At baseline (pre-intervention) and 1-hour of intervention
Plan to share: Yes — All de-identified data will be shared on github.
Supporting information: Study protocol, Sap, Icf, Csr, Analytic code
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver